Cosibelimab (Anti-B7-H1 / PD-L1 / CD274) | PD-1/PD-L1 antibody

Cosibelimab (Anti-B7-H1 / PD-L1 / CD274) is an immunoglobulin G1 (IgG1), human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.64 KD.

Purity & Quality Control

≥99

Choose Selective PD-1/PD-L1 Inhibitors

Biological Activity

Description	Cosibelimab (Anti-B7-H1 / PD-L1 / CD274) is an immunoglobulin G1 (IgG1), human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.64 KD.

References
[1] Akinleye A, et al. J Hematol Oncol. 2019 Sep 5;12(1):92.

References

[1] Akinleye A, et al. J Hematol Oncol. 2019 Sep 5;12(1):92.

Product Details

CAS No.	2216751-26-5
Molecular Weight	144.64
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100mMPro-Ac,20mMArg-Ac，pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field